The Expression of IL-15 and Its Receptor in Decidua

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2005 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00173758
First received: September 13, 2005
Last updated: December 20, 2005
Last verified: June 2005
  Purpose

Human decidual tissue appears to play an important role not only in nurturing the implanted embryos, but also in preventing its rejection by the maternal immune system. Insight into the maternal immunologic modulations during implantation is our main research interests. Our previous studies have shown that most lymphocytes in deciduae are natural killer cells. However, their phenotype is CD16-CD56+CD3-, which is different from that of peripheral natural killer cells. More importantly their cytotoxic activity is decreased and they can’t attack the cytotrophoblasts. All of these contributes to no rejection developing at the fetomaternal interface and are related to success of pregnancy.

In 1994, a new cytokine IL-15 was first discovered, which could act on the IL-15 and IL-2 receptors to stimulate the activation and propagation of the lymphocytes. Let us want to study the critical role of IL-15 in the endometrial lymphocytes. In this study, we try to analyze the distribution of IL-15 and its receptor in deciduae. We will clarify whether the IL-15 receptor exists on the decidual natural killer cells and it is regulated by sexual hormones or not and whether their cytotoxic activity will change after IL-15 action. Furthermore, we will demonstrated whether the IL-15 receptor exists on the embryo cells and IL-15 might improve the quality of the embryo. We also design a co-culture system of the embryo and autologous endometrial cells to improve the success rate of in vitro fertilization.


Condition Intervention
Pregnancy
Infertility
Procedure: co-culture of embryos and endometrial cells

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: The Expression of IL-15 and Its Receptor in Uterine NK Cells and Clinical Applications

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • Fertilization rate of oocytes
  • Implantation rate of embryos
  • Pregnancy rate

Estimated Enrollment: 30
Study Start Date: September 2005
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   20 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Ages between 20 and 40 years
  • Written informed consent
  • Regular cycles, between 21 and 35 days, within the last 6 months before pregnancy
  • Early pregnancy between 4 to 10 weeks of gestation

Exclusion Criteria:

  • Abnormal vaginal bleeding
  • Concomitant treatment with other drugs
  • Autoimmune diseases
  • Pelvic inflammation with last 3 months
  • Having any associated malignancy
  • Unable or unwilling to comply fully with the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00173758

Contacts
Contact: Kuang-Han Chao, M.D. 886-2-2312-3456 ext 5539 khchao@ntumc.org

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 100
Contact: Kuang-Han Chao, M.D.    886-2-2312-3456 ext 5539    khchao@ntumc.org   
Principal Investigator: Kuang-Han Chao, M.D.         
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Kuang-Han Chao, M.D. Department of Obstetrics and Gynecology, National Taiwan University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00173758     History of Changes
Other Study ID Numbers: 9361701276
Study First Received: September 13, 2005
Last Updated: December 20, 2005
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
IL-15
IL-15 receptor
decidual natural killer cells
endometrium

Additional relevant MeSH terms:
Infertility
Genital Diseases, Female
Genital Diseases, Male

ClinicalTrials.gov processed this record on October 23, 2014